This article was originally published in The Tan Sheet
Bristol-Myers Squibb submits citizen petition to FDA Nov. 12 requesting the agency not finalize its draft guidance for industry - "Topical Dermatological Drug Product NDAs and ANDAs: In Vivo Bioavailability, Bioequivalence, In Vitro Release and Associated Studies" - until FDA resolves certain outstanding issues. BMS suggests FDA's new dermatopharmacokinetics (DPK) method "has not been adequately tested" and the agency's proposed "standard of qualitative 'functional similarity' of inactive ingredients between test and reference products is broad and inappropriate." FDA issued the draft guidance in 1998 (1"The Tan Sheet" June 29, 1998, p. 25)
You may also be interested in...
SKIN STRIPPING ADEQUATE FOR DERMATOLOGIC BIOEQUIVALENCE STUDIES for most topical drugs, an FDA draft guidance states. "Skin strip-ping," or dermatopharmacokinetics (DPK), "principles should be generally applicable to all topical dermatological drug products including antifungal, antiviral, anti-acne, antibiotic, corticosteroid and vaginally applied drug products," the draft guidance states. The draft, "Topical Dermatological Drug Product NDAs and ANDAs -- In Vivo Bioavailability, Bioequivalence, In Vitro Release and Associated Studies," was published in the Federal Register June 18.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning